Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: Preferential presence in HTLV type I- infected neurologic patients versus healthy virus carriers

AIDS Research and Human Retroviruses

Volumn 16, Issue 10, 2000, Pages 965-972

  Lezin, A ^a   Buart, S ^b   Smadja, D ^c   Akaoka, H ^b   Bourdonne O ^a   Perret Liaudet, A ^d   Cesaire R ^a   Belin, M F ^b   Giraudon, Pascale ^b  

^a Laboratoire de Virologie   (France)

^b INSERM   (France)

^c CHU La Meynard   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GELATINASE B; NEOPTERIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LYMPHOCYTIC INFILTRATION; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CARRIER;

BIOLOGICAL MARKERS; CARRIER STATE; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPTERIN; PARAPARESIS, TROPICAL SPASTIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 0034235719     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050058380     Document Type: Article

References (61)

1. 1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, and Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-7419.
2. 2. Hinuma Y, Nagata K, Hanaoka M, et al.: Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981;78:6476-6480.
3. 3. Gessain A, Barin F, Vernant J, et al.: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-410.
4. 4. Osame M, Usuku K, Izumo S, et al.: HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-1032.
5. 5. Mahieux R, Ibrahim F, Mauclere P, et al.: Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-I) strains: Identification of a new and distinct HTLV-I molecular subtype in Central Africa and in Pygmies. J Virol 1997;71:1317-1333.
6. 6. Gessain A: Virological aspects of tropical spastic paraparesis/ HTLV-I associated myelopathy and HTLV-I infection. J Neurovirol 1996;2:299-306. [See comments]
7. 7. Osame M, Nakagawa M, Umehara F, et al.: Recent studies on the epidemiology, clinical features and pathogenic mechanisms of HTLV-I associated myelopathy (HAM/TSP) and other diseases associated to HTLV. J Neurovirol 1997;3(Suppl. 1):S50-S51.
8. 8. Nagai M, Usuku K, Matsumoto W, et al.: Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998;4:586-593.
9. 9. Watanabe H, Nakamura T, Nagasato K, et al.: Exaggerated messenger RNA expression of inflammatory cytokines in human T-cell lymphotropic virus type I-associated myelopathy. Arch Neurol 1995;52:276-280.
10. 10. Tendler C, Greenberg S, Burton J, et al.: Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem 1991;46:302-311.
11. 11. Buckle GJ, Hafler DA, and Hollsberg P: HTLV-I-induced T-cell activation. J Acquir Immune Defic Syndr Hum Retroviral 1996; 13(Suppl. 1):S107-S113.
12. 12. Moritoyo T, Reinhart TA, Moritoyo H, et al.: Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. Ann Neurol 1996;40:84-90.
13. 13. Umehara F, Izumo S, Ronquillo A, Matsumuro K, Sato E, and Osame M: Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1994;53: 72-77.
14. 14. Hollsberg P and Hafler DA: What is the pathogenesis of human T-cell lymphotropic virus type I-associated myelopathy/tropic al spastic paraparesis? Ann Neurol 1995;37:143-145. [Editorial; comment].
15. 15. Utz U, Banks D, Jacobson S, and Biddison WE: Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-I) Tax-specific CD8+ cytotoxic T lymphocytes from patients with HTLV-I-associated disease: Evidence for oligoclonal expansion. J Virol 1996;70:843-851.
16. 16. Ijichi S, Izumo S, Eiraku N, et al.: An autoaggressive process against bystander tissues in HTLV-I-infected individuals: A possible pathomechanism of HAM/TSP. Med Hypotheses 1993;41: 542-547.
17. 17. Giraudon P, Buart S, Bernard A, Thomasset N, and Belin MF: Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Prog Neurobiol 1996;49:169-184.
18. 18. Apodaca G, Rutka JT, Bouhana K, et al.: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990;50:2322-2329.
19. 19. Muir D: Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. Clin Exp Metastasis 1995;13:303-314.
20. 20. Chandler S, Miller KM, Clements JM, et al.: Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview. J Neuroimmunol 1997;72:155-161.
21. 21. Borden P and Heller RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 1997;7:159-178.
22. 22. Edwards DR, Beaudry PP, Laing TD, et al.: The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int J Obes Relat Metab Disord 1996;20(Suppl. 3):S9-S15.
23. 23. Werb Z: ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997;91:439-442.
24. 24. Gijbels K, Masure S, Carton H, and Opdenakker G: Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41: 29-34.
25. 25. Cossins JA, Clements JM, Ford J, et al.: Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berlin) 1997;94:590-598.
26. 26. Opdenakker G and Van Damme J: Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994;15:103-107.
27. 27. Maeda A and Sobel RA: Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309.
28. 28. Cuzner ML, Gveric D, Strand C, et al.: The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evaluation. J Neuropathol Exp Neurol 1996;55:1194-1204.
29. 29. Giraudon P, Bernard A, Malcus C, Dufay N, Desgranges C, and Belin M: Retroviral infection (HTLV-I) induces cytokine-regulated immunomodulation and cytotoxicity of medulloblastom a cells. J Neuropathol Exp Neurol 1995;54:165-174.
30. 29a. Giraudon P, Szymocha R, Buart S, Bernard A, Cartier L, Belin MF, and Akaoka H: T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases (MMPs) and their endogenous inhibitors, TIMPs, in human astrocytes: Relevance to HTLV-I-induced neurological disease. J Immunol 2000;164:2718-2727.
31. 30. Giraudon P, Thomasset N, Bernard A, Verrier B, and Belin MF: Induction of MMP9 (92 kD a gelatinase) activity and expression of tissue inhibitor of metalloproteinase-2 mRNA (TIMP-2) in primitive neuroectoderm al cells infected with retrovirus HTLV-I. Eur J Neurosci 1995;7:841-848.
32. 31. Giraudon P, Vernant JC, Confavreux C, Belin MF, and Desgranges C: Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-I infected patients with tropical spastic paraparesis. Neurology 1998;50:1920.
33. 32. Osame M: HAM/TSP: Global review and WHO diagnostic guidelines. In: Advances in Neurology (Chopra J, ed.). Elsevier Science, Amsterdam, 1991, pp. 265-271.
34. 33. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, and Werb Z: Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986;261:2814-2818.
35. 34. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, and Ford CC: Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
36. 35. Giraudon P, Buart S, Bernard A, and Belin MF: Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): Possible involvement in neurodegenerative processes. Mol Psychiatry 1997;2:107-110.
37. 36. Metz CE, Herman BA, and Roe CA: Statistical comparison of two ROC curve estimates obtained from partially-paired datasets. Med Decis Making 1998;18:110-121.
38. 37. Kleiner DJ and Stetler-Stevenson W: Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993; 5:891-897.
39. 38. Leppert D, Ford J, Stabler G, et al.: Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-2334. [In Process Citation]
40. 39. Strong RK, Bratt T, Cowland JB, Borregaard N, Wiberg FC, and Ewald AJ: Expression, purification, crystallization and crystallographic characterization of dimeric and monomeric human neutrophil gelatinase associated lipocalin (NGAL). Acta Crystallogr D Biol Crystallogr 1998;54:93-95.
41. 40. Immanuel C, Swamy R, Kannapiran M, et al.: Neopterin as a marker for cell-mediated immunity in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997;1:175-180.
42. 41. Maloney EM, Brown LM, Kurman CC, et al.: Temporal variability in immunological parameters: Peripheral blood mononuclear cell subsets, serum immunoglobulins, and soluble markers of immune system activation. J Clin Lab Anal 1997;11:190-195.
43. 42. Nomoto M, Utatsu Y, Soejima Y, and Osame M: Neopterin in cerebrospinal fluid: A useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis. Neurology 1991;41: 457.
44. 43. Nakagawa M, Izumo S, Ijichi S, et al.: HTLV-I-associated myelopathy: Analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995;1:50-61.
45. 44. Umehara F, Okada Y, Fujimoto N, Abe M, Izumo S, and Osame M: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1998;57:839-849.
46. 45. Backstrom JR, Lim GP, Cullen MJ, and Tokes ZA: Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996;16:7910-7919.
47. 46. Baker AH, Zaltsman AB, George SJ, and Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998;101:1478-1487.
48. 47. Bian J, Wang Y, Smith MR, et al.: Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 1996;17:1805-1811.
49. 48. Uhm JH, Dooley NP, Oh LY, and Yong VW: Oligodendrocytes utilize a matrix metallo proteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 1998;22:53-63.
50. 49. Sato H, Kita M, and Seiki M: v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993;268:23460-23468.
51. 50. Cuzner ML and Norton WT: Biochemistry of demyelination. Brain Pathol 1996;6:231-242.
52. 51. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, and Campbell IL: Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998;152:729-741.
53. 52. Zeng Y, Rosborough RC, Li Y, Gupta AR, and Bennett J: Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases-3 (TIMP-3)-encoding gene. Dev Dyn 1998;211:228-237.
54. 53. Cartier LM, Cea JG, Vergara C, Araya F, and Born P: Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: An axomyelinic degeneration of the central nervous system. J Neuropathol Exp Neurol 1997;56:403-413.
55. 54. Wachter H, Fuchs D, Hausen A, Reibnegger G, and Werner ER: Neopterin as marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 1989;27: 81-141.
56. 55. Gisslen M, Hagberg L, Fuchs D, Norkrans G, and Svennerholm B: Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: A longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:291-295.
57. 56. Weiss G, Thuma PE, Biemba G, Mabeza G, Werner ER, and Gordeuk VR: Cerebrospinal fluid levels of biopterin, nitric oxide metabolites, and immune activation markers and the clinical course of human cerebral malaria. J Infect Dis 1998;177:1064-1068.
58. 57. Umehara F, Izumo S, Nakagawa M, et al.: Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1993;52: 424-430.
59. 58. Talhouk RS, Bissell MJ, and Werb Z: Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992;118:1271-1282.
60. 59. Celio MR and Blumcke I: Perineuronal nets - a specialized form of extracellular matrix in the adult nervous system. Brain Res Brain Res Rev 1994;19:128-145.
61. 60. Celio MR, Spreafico R, De Biasi S, and Vitellaro-Zuccarello L: Perineuronal nets: Past and present. Trends Neurosci 1998;21: 510-511.